Laboratory Corporation of America: OmniSeq Insight for ctDNA

Laboratory Corporation of America has launched its OmniSeq Insight circulating tumor DNA assay as part of its comprehensive genomic profiling portfolio. The new assay complements the existing OmniSeq Insight product by evaluating the same biomarkers, enabling delivery of integrated and uniform genomic variants, tumor mutational burden and microsatellite instability detection from blood and tissue specimens to support exploratory and longitudinal biopharmaceutical studies.